Cash and Short Term Investments (Quarterly) Chart

View Cash and Short Term Investments (Quarterly) for REGN.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash and Short Term Investments (Quarterly) Chart
Start Trial

Historical Cash and Short Term Investments (Quarterly) Data

View and export this data back to 1998. Start Trial.
Date Value
June 30, 2026 8.005B
March 31, 2026 8.762B
December 31, 2025 8.611B
September 30, 2025 8.450B
June 30, 2025 7.489B
March 31, 2025 8.349B
December 31, 2024 9.012B
September 30, 2024 9.796B
June 30, 2024 9.816B
March 31, 2024 10.52B
December 31, 2023 10.84B
September 30, 2023 9.914B
June 30, 2023 8.933B
March 31, 2023 8.960B
December 31, 2022 7.742B
September 30, 2022 7.022B
June 30, 2022 7.566B
March 31, 2022 7.051B
December 31, 2021 5.695B
September 30, 2021 5.788B
June 30, 2021 3.911B
March 31, 2021 3.504B
December 31, 2020 3.587B
September 30, 2020 3.026B
June 30, 2020 3.144B
Date Value
March 31, 2020 4.003B
December 31, 2019 3.214B
September 30, 2019 2.878B
June 30, 2019 2.670B
March 31, 2019 3.232B
December 31, 2018 2.810B
September 30, 2018 2.192B
June 30, 2018 1.684B
March 31, 2018 1.625B
December 31, 2017 1.410B
September 30, 2017 1.379B
June 30, 2017 1.268B
March 31, 2017 1.307B
December 31, 2016 1.039B
September 30, 2016 1.408B
June 30, 2016 1.045B
March 31, 2016 849.18M
December 31, 2015 1.045B
September 30, 2015 895.64M
June 30, 2015 604.25M
March 31, 2015 742.16M
December 31, 2014 900.48M
September 30, 2014 1.042B
June 30, 2014 816.91M
March 31, 2014 648.13M

Cash and Short Term Investments Definition

Represents the sum of cash and short term investments.

Read full definition.

Cash and Short Term Investments (Quarterly) Range, Past 5 Years

View Cash and Short Term Investments (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash and Short Term Investments (Quarterly) Benchmarks

View Cash and Short Term Investments (Quarterly) Benchmarks
Start Trial
Alnylam Pharmaceuticals, Inc. 3.308B
AbbVie, Inc. 6.569B
Gilead Sciences, Inc. 4.882B
Amgen, Inc. 13.99B
Biogen, Inc. 1.285B